Long-term risks after splenectomy among 8,149 cancer-free American veterans: a cohort study with up to 27 years follow-up.
Sigurdur Y Kristinsson, Gloria Gridley, Robert N Hoover...
https://pubmed.ncbi.nlm.nih.gov/24056815Actively Recruiting
Age: 18Years +
All Genders
ID04199403
Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients
Led by Poitiers University Hospital · Updated on 2024-02-01
6000
Participants Needed
12
Research Sites
N/A
Total Duration
On this page
Sponsors
P
Poitiers University Hospital
Lead Sponsor
P
Pr Pierre BUFFET Institut National de la Transfusion Sanguine
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to understand the risks of complications in patients without a spleen (asplenic patients) in France. These patients may have lost spleen function due to surgery for trauma, cancer, autoimmune disease, or diagnostic reasons, or due to treatments like radiotherapy or splenic artery embolism. The study focuses on evaluating the risks of infections, cancer, and blood clot diseases in this group, as these complications are not well understood. The study observes patients with asplenia caused by splenectomy, splenic artery embolization, or radiotherapy. It plans a long-term follow-up to assess how splenic function and immunity change over time among different patient groups. New tools to assess residual spleen function will be used to improve patient management and better estimate the rates of infectious and non-infectious complications. Participants will be followed prospectively with evaluations over a period of three years. Researchers will monitor and assess complications and risk factors during this time. The main outcome measured is the assessment of complication risk factors related to asplenia. This observational study does not involve treatments but focuses on detailed follow-up of health outcomes and splenic function.
CONDITIONS
Brief Title
Assessment of Complication Risk Factors in a French National Cohort of Asplenic Patients
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
- 18 years old or older
- Have asplenia due to splenectomy, splenic artery embolization, or radiotherapy
You will not qualify if you...
- Genetic asplenia including sickle cell disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Long-term Monitoring
Duration - Up to 3 years
Participants are observed over time to assess the incidence of infectious and non-infectious complications related to asplenia.
Trial Site Locations
Total: 12 locations
1
C.H. d'Angoulême
Angoulême, France, 16959
Actively Recruiting
2
C.H. Victor Dupouy
Argenteuil, France, 95100
Actively Recruiting
3
C.H. de Béthune
Béthune, France, 62660
Actively Recruiting
4
Hôpitaux de Chartres
Chartres, France, 28019
Actively Recruiting
5
C.H.U. de Lille
Lille, France, 59037
Actively Recruiting
6
C.H.U. de Montpellier
Montpellier, France, 34295
Actively Recruiting
7
Hôtel-Dieu - CHU de Nantes
Nantes, France, 44093
Actively Recruiting
8
C.H.U. de Poitiers
Poitiers, France, 86000
Actively Recruiting
9
C.H.U. de Rouen
Rouen, France, 76031
Not Yet Recruiting
10
C.H.U. de Toulouse
Toulouse, France, 31059
Actively Recruiting
11
C.H. de Tourcoing
Tourcoing, France, 59208
Actively Recruiting
12
C.H. de Valenciennes
Valenciennes, France, 59300
Actively Recruiting
Loading map...
Research Team
M
Mathieu PUYADE, MD
C
Corinne Lorrain
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Structure and function of the spleen.
Reina E Mebius, Georg Kraal
https://pubmed.ncbi.nlm.nih.gov/16056254Splenic artery embolization versus splenectomy: Analysis for early in-hospital infectious complications and outcomes.
Alberto Aiolfi, Kenji Inaba, Aaron Strumwasser...
https://pubmed.ncbi.nlm.nih.gov/28459796